Patents
Literature
6 results about "Dexpanthenol" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An alcoholic analogue of D-pantothenic acid and cholinergic agent. Dexpanthenol acts as a precursor of coenzyme A necessary for acetylation reactions and is involved in the synthesis of acetylcholine. Although the exact mechanism of the actions of dexpanthenol is unclear, it may enhance the effect of acetylcholine. Dexpanthenol acts on the gastrointestinal tract and increases lower intestinal motility. It is also applied topically to the skin to relieve itching and to promote healing.
Nasal ointment
The present invention relates to a nasal ointment comprising hyaluronic acid, dexpanthenol and an aloe vera extract. The present invention also relates to the use of hyaluronic acid, dexpanthenol and an aloe vera extract for manufacturing an agent used in various medical procedures. The invention also relates to a method for the preparation of said nasal ointment.
Owner:VECTORONA SÀRL
Combination preparation for the treatment of acute and chronic rhinosinusitis and / or allergic rhinitis
PCT designated stage expiredWO2025119815A1Pharmaceutical delivery mechanismAmide active ingredientsMometasoneBULK ACTIVE INGREDIENT
The present application provides a novel combination preparation for use in the treatment of acute, chronic and allergic rhinosinusitis and / or allergic rhinitis which does not cause dry nasal mucosa and is very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient in the form of a nasal spray.
Owner:ROTH BERNHARD
Combination of dexpanthenol, methyluracil and chloramphenicol for inhibiting inflammatory processes
PCT designated stageWO2026054671A1Antibacterial agentsDigestive systemPharmaceutical SubstancesTraumatology
The present invention relates to medicine and the pharmaceutical industry, and more particularly to agents capable of inhibiting inflammatory processes, and even more particularly to agents that have an antimicrobial, sorptive, angioprotective and wound-healing effect on local inflammatory processes of the skin and soft tissues, for use in surgery, traumatology and dermatology. What is proposed in the present invention is a combination including dexpanthenol, methyluracil and chloramphenicol, and also a pharmaceutical composition based thereon.
Owner:RYZHKOVA NATALJA SERGEEVNA
Compositions and methods of treatment with glutathione
A topical composition comprising a nanonised L-glutathione and cyclodextrin complex, together with ascorbic acid in a weight ratio of glutathione to ascorbic acid from 7:1 to 15:1 and from 1:1 to 1:15 and a further compound comprising dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate or acetyl-L-cysteine, which composition is topically administered for treating the symptoms of viral infection including COVID-19 and influenza, and for treating herpes simplex, herpes zoster, post herpetic neuralgia, genital herpes, alcohol detoxification, high triglycerides, age or liver spots and lupus.
Owner:AURO PHARMACEUTICALS INC
Combination preparation for the treatment of acute and chronic rhinosinusitis
The present application provides a novel combination preparation for us in the treatment of acute, chronic and allergic rhinosinusitis which does not cause dry nasal mucosa and is nevertheless very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient
Owner:ROTH BERNHARD
Dexpanthenol GEL forming solution and method of preparation thereof
PCT designated stageWO2025253406A1Organic active ingredientsSenses disorderDiseasePharmaceutical medicine
The present invention provides a gel forming solution composition comprising dexpanthenol or its pharmaceutically acceptable salt, gel forming agent and one or more pharmaceutically acceptable excipients, wherein the composition forms gel on contact with lacrimal fluid. The present invention provides a gel forming solution composition for the treatment of dry eye disease or corneal epithelial damage. The invention further provides a process for preparation of such gel forming solution composition to treat dry eye disease or corneal epithelial damage.
Owner:SENTISS PHARMA